Israel-Canada venture will promote a culture of discovery, innovation, excellence and commercialization of new therapies for heart disease.
The Technion – Israel Institute of Technology
has joined forces with Canada’s University Health Network
(UHN) to establish the Technion – UHN
International Centre for Cardiovascular Innovation (Technion – UHN ICCI). Some C$10 million of the $75 million dollar project budget has been raised.
“Heart disease is the major cause of death in OEDC countries, and the second leading cause of death in Israel and Canada. This collaboration holds significant potential for the development of new cardiovascular devices and regenerative medicine therapies, innovations that will benefit not only residents of Canada and Israel, but all mankind,” said Dr. Barry Rubin, the Medical Director of the Peter Munk Cardiac Centre in Toronto.
Canadian partners in the venture include the McEwen Centre for Regenerative Medicine and the Peter Munk Cardiac Centre.
The goal of the new center is to develop “new medical technologies and innovative applications in areas such as medical devices and stem cell therapies – medical innovations with substantial commercial potential, and provide a cure to millions of patients worldwide,” according to a statement.
The new center will see the emergence of the next generation of scientists and researchers who will specialize in the emerging field of stem cell research that has the potential to provide new therapies for the treatment of a range of debilitating diseases, said Professor Boaz Golany, Vice President for External Relations and Resource Development at the Technion.
Technion President Professor Peretz Lavie said that the establishment of this new center amalgamates the Technion’s extensive international activities. “Only by combining forces through collaboration with leading scientists and researchers from around the world, will breakthroughs be realized,” he said. “I’m very pleased that a worldwide leader in regenerative medicine and the management of patients with heart disease, UHN in Canada, chose the Technion as its partner in this venture, and I’m convinced that the developments coming out of this new centre will provide a cure to millions of patients worldwide. Not without good reason was the Technion selected as a partner, for it is a global leader in biomechanical engineering and stem cell research.”Photo by Shutterstock.com